Nuvalent Shares Leap Premarket on Takeover by GSK

By Colin Kellaher


Shares of Nuvalent surged in premarket trading Tuesday after the clinical-stage biopharmaceutical company agreed to be acquired by U.K. pharmaceutical company GSK for $10.6 billion.

GSK is paying $124 a share in cash for Nuvalent, a 40% premium to Monday's closing price of $88.49 for the Cambridge, Mass., company.

The deal is slated to close in the third quarter.

Nuvalent shares were recently up more than 38% to $122.51 in premarket trading.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

June 09, 2026 06:00 ET (10:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.

Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.

Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.

Popular

Sponsor Center